You are here: Home » PTI Stories » National » News
Business Standard

Aurobindo Pharma shares soar 7%; mcap rises by Rs 2,447 cr

Press Trust of India  |  New Delhi 

of Pharma today surged almost 7 per cent as the company received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on dialysis.

The stock jumped 6.94 per cent to close at Rs 643.20 on During the day, it rose sharply by 7.78 per cent to Rs 648.30.



At NSE, of the company gained 6.94 per cent to end at Rs 643.90.

Following the rise in the stock, the company's market valuation went up by Rs 2,446.96 crore to Rs 37,683.96 crore.

In terms of volume, 9.13 lakh of the company were traded on and over one crore changed hands at during the day.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm, the drug maker said in a filing today.

Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Aurobindo Pharma shares soar 7%; mcap rises by Rs 2,447 cr

Shares of Aurobindo Pharma today surged almost 7 per cent as the company received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on dialysis. The stock jumped 6.94 per cent to close at Rs 643.20 on BSE. During the day, it rose sharply by 7.78 per cent to Rs 648.30. At NSE, shares of the company gained 6.94 per cent to end at Rs 643.90. Following the rise in the stock, the company's market valuation went up by Rs 2,446.96 crore to Rs 37,683.96 crore. In terms of volume, 9.13 lakh shares of the company were traded on BSE and over one crore shares changed hands at NSE during the day. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm, the drug maker said in a BSE filing today. Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on ... of Pharma today surged almost 7 per cent as the company received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on dialysis.

The stock jumped 6.94 per cent to close at Rs 643.20 on During the day, it rose sharply by 7.78 per cent to Rs 648.30.

At NSE, of the company gained 6.94 per cent to end at Rs 643.90.

Following the rise in the stock, the company's market valuation went up by Rs 2,446.96 crore to Rs 37,683.96 crore.

In terms of volume, 9.13 lakh of the company were traded on and over one crore changed hands at during the day.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm, the drug maker said in a filing today.

Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Aurobindo Pharma shares soar 7%; mcap rises by Rs 2,447 cr

of Pharma today surged almost 7 per cent as the company received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on dialysis.

The stock jumped 6.94 per cent to close at Rs 643.20 on During the day, it rose sharply by 7.78 per cent to Rs 648.30.

At NSE, of the company gained 6.94 per cent to end at Rs 643.90.

Following the rise in the stock, the company's market valuation went up by Rs 2,446.96 crore to Rs 37,683.96 crore.

In terms of volume, 9.13 lakh of the company were traded on and over one crore changed hands at during the day.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm, the drug maker said in a filing today.

Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22